Subscribe To
ABUS / Arbutus Biopharma (ABUS) Stock: Why The Price Jumped Today
ABUS News
By GlobeNewsWire
October 24, 2023
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage more_horizontal
By Zacks Investment Research
September 12, 2023
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA more_horizontal
By MarketBeat
September 7, 2023
3 Stocks to Buy For the COVID Resurgence
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will b more_horizontal
By Zacks Investment Research
August 3, 2023
Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to lo more_horizontal
By GlobeNewsWire
June 7, 2023
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging more_horizontal
By Zacks Investment Research
May 9, 2023
Arbutus (ABUS) Upgraded to Buy: Here's Why
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the st more_horizontal
By Zacks Investment Research
May 4, 2023
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year. more_horizontal
By Zacks Investment Research
May 4, 2023
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to lo more_horizontal